{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:48:28Z","timestamp":1765806508242},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1208\/aapsj070107","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T12:16:44Z","timestamp":1126613804000},"page":"E54-E58","source":"Crossref","is-referenced-by-count":21,"title":["New questions regarding bioequivalence of levothyroxine preparations: A Clinician's response"],"prefix":"10.1208","volume":"7","author":[{"given":"William L.","family":"Green","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"71054_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1089\/105072503321582088","volume":"13","author":"JV Hennessey","year":"2003","unstructured":"Hennessey JV. Levothyroxine a new drug? Since when? How could that be?.Thyroid 2003;13:279\u2013282.","journal-title":"Thyroid"},{"key":"71054_CR2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-119-6-199309150-00009","volume":"119","author":"SJ Mandel","year":"1993","unstructured":"Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease.Ann Intern Med. 1993;119:492\u2013502.","journal-title":"Ann Intern Med."},{"key":"71054_CR3","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/jama.273.10.808","volume":"273","author":"PA Singer","year":"1995","unstructured":"Singer PA, Cooper DS, Levy EG et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association.JAMA. 1995;273:808\u2013812.","journal-title":"JAMA"},{"key":"71054_CR4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4158\/1934-2403-8.6.457","volume":"8","author":"AACE Thyroid Task Force","year":"2002","unstructured":"AACE Thyroid Task Force. American Association of Clinical endorrinologist medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism.Endocr Pract. 2002;8:457\u2013469.","journal-title":"Endocr Pract."},{"key":"71054_CR5","unstructured":"McDermott MT. American College of Physicians, Physicians' Information and Education Resource: Hypothyroidism. Available at: http:\/\/pier.acponline. org\/physicians\/diseases\/d238\/d238.html.Accessed September 20, 2004."},{"key":"71054_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1365-2265.1999.00639.x","volume":"50","author":"VJ Pop","year":"1999","unstructured":"Pop VJ, Kuijpens JL, van Baar AL, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy.Clin Endocrinol (Oxf). 1999;50:149\u2013155.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"71054_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJM199908193410801","volume":"341","author":"JE Haddow","year":"1999","unstructured":"Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid dificiency during pregnancy and subsequent neuropsychological development of the child.N Engl J Med. 1999;341:549\u2013555.","journal-title":"N Engl J Med."},{"key":"71054_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa040079","volume":"351","author":"EK Alexander","year":"2004","unstructured":"Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidims.N Engl J Med. 2004;351:241\u2013249.","journal-title":"N Engl J Med."},{"key":"71054_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/105072503321086962","volume":"13","author":"Z Baloch","year":"2003","unstructured":"Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.Thyroid. 2003;13:3\u2013126.","journal-title":"Thyroid."},{"key":"71054_CR10","volume-title":"The Thyroid Solution","author":"R Arem","year":"1999","unstructured":"Arem R.The Thyroid Solution. New York, NY: Ballantine Books; 1999."},{"key":"71054_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJM199902113400603","volume":"340","author":"R Bunevicius","year":"1999","unstructured":"Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ, Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism.N Engl J Med. 1999;340:424\u2013429.","journal-title":"N Engl J Med."},{"key":"71054_CR12","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1210\/jc.2003-030139","volume":"88","author":"AM Sawka","year":"2003","unstructured":"Sawka AM, Gerstein HC, Marriott MJ, MacQueen GM, Joffe RT. Does a combination regiment of thyroxine (T4) and 3,5,3?-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial.J Clin Endocrinol Metab. 2003;88:4551\u20134555.","journal-title":"J Clin Endocrinol Metab."},{"key":"71054_CR13","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1001\/jama.290.22.2952","volume":"290","author":"PW Clyde","year":"2003","unstructured":"Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.JAMA. 2003;290:2952\u20132958.","journal-title":"JAMA."},{"key":"71054_CR14","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1210\/jc.2003-030249","volume":"88","author":"JP Walsh","year":"2003","unstructured":"Walsh JP, Shiels L, Lim EM, et al. Combined thyroxine\/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism.J Clin Endocrinol Metab. 2003;88:4543\u20134550.","journal-title":"J Clin Endocrinol Metab."},{"key":"71054_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1089\/105072502760339406","volume":"12","author":"I Shimon","year":"2002","unstructured":"Shimon I, Cohen O, Lubetsky A, Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.Thyroid. 2002;12:823\u2013827.","journal-title":"Thyroid."},{"key":"71054_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1080\/078538902321117760","volume":"34","author":"NJ McGriff","year":"2002","unstructured":"McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical out-comes in thyroid cancer.Ann Med. 2002;34:554\u2013564.","journal-title":"Ann Med."},{"key":"71054_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2265.1988.tb01219.x","volume":"28","author":"D Carr","year":"1988","unstructured":"Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment.Clin Endocrinol (Oxf). 1988;28:325\u2013333.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"71054_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1172\/JCI111245","volume":"73","author":"SM Lum","year":"1984","unstructured":"Lum SM, Nicoloff JT, Spencer CA, Kaptein EM. Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man.J Clin Invest. 1984;73:570\u2013575.","journal-title":"J Clin Invest."},{"key":"71054_CR19","first-page":"74","volume":"14","author":"JT Nicoloff","year":"1984","unstructured":"Nicoloff JT, Lum SM, Spencer CA, Morris R. Peripheral autoregulation of thyroxine to triiodothyronine conversion in man.Horm Metab Res Suppl. 1984;14:74\u201379.","journal-title":"Horm Metab Res Suppl."},{"key":"71054_CR20","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJM199411103311901","volume":"331","author":"CT Sawin","year":"1994","unstructured":"Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.N Engl J Med. 1994;331:1249\u20131252.","journal-title":"N Engl J Med."},{"key":"71054_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1210\/jc.77.2.334","volume":"77","author":"B Biondi","year":"1993","unstructured":"Biondi B, Fazio S, Carella C. et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine.J Clin Endocrinol Metab. 1993;77:334\u2013338.","journal-title":"J Clin Endocrinol Metab."},{"key":"71054_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/jc.85.1.159","volume":"85","author":"G Mercuro","year":"2000","unstructured":"Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring.J Clin Endocrinol Metab. 2000;85:159\u2013164.","journal-title":"J Clin Endocrinol Metab."},{"key":"71054_CR23","doi-asserted-by":"crossref","first-page":"750","DOI":"10.7326\/0003-4819-130-9-199905040-00016","volume":"130","author":"SL Greenspan","year":"1999","unstructured":"Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity.Ann Intern Med. 1999;130:750\u2013758.","journal-title":"Ann Intern Med."},{"key":"71054_CR24","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/0002-9343(87)90219-1","volume":"82","author":"DS Ross","year":"1987","unstructured":"Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible results of prolonged suppression of the pituitary-thyroid axis with L-thyroxine.Am J Med. 1987;82:1167\u20131170.","journal-title":"Am J Med."},{"key":"71054_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1056\/NEJMcp010145","volume":"345","author":"AD Toft","year":"2001","unstructured":"Toft AD. Clinical practice. Subclinical hyperthyroidism.N Engl J Med. 2001;345:512\u2013516.","journal-title":"N Engl J Med."},{"key":"71054_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/thy.1993.3.17","volume":"3","author":"BL Solomon","year":"1993","unstructured":"Solomon BL, Wartofsky L, Burman KD. Prevalence of fractures in postmenopausal women with thyroid disease.Thyroid. 1993;3:17\u201323.","journal-title":"Thyroid."},{"key":"71054_CR27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.7326\/0003-4819-134-7-200104030-00009","volume":"134","author":"DC Bauer","year":"2001","unstructured":"Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone.Ann Intern Med. 2001;134:561\u2013568.","journal-title":"Ann Intern Med."},{"key":"71054_CR28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-132-4-200002150-00004","volume":"132","author":"AE Hak","year":"2000","unstructured":"Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.Ann Intern Med. 2000;132:270\u2013278.","journal-title":"Ann Intern Med."},{"key":"71054_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1365-2265.1977.tb01341.x","volume":"7","author":"WM Tunbridge","year":"1977","unstructured":"Tunbridge WM, Evered DC, Hall R, et al. Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure.Clin Endocrinol (Oxf). 1977;7:495\u2013508.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"71054_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1001\/archinte.160.4.526","volume":"160","author":"GJ Canaris","year":"2000","unstructured":"Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study.Arch Intern Med. 2000;160:526\u2013534.","journal-title":"Arch Intern Med."},{"key":"71054_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/jc.87.2.489","volume":"87","author":"JG Hollowell","year":"2002","unstructured":"Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994) National Health and Nutrition Examination Survey (NHANES III).J Clin Endocrinol Metab. 2002;87:489\u2013499.","journal-title":"J Clin Endocrinol Metab."},{"key":"71054_CR32","unstructured":"Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry: Levothyroxine Sodium Tablets\u2014In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing. Available at: http:\/\/www.fda.gov\/cder\/guidance\/364 fnl.htm. Accessed March 8, 2000."},{"key":"71054_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/105072504773297867","volume":"14","author":"V Blakesley","year":"2004","unstructured":"Blakesley V, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?Thyroid. 2004;14:191\u2013200.","journal-title":"Thyroid."},{"key":"71054_CR34","unstructured":"Yu LX. Letter to ANDA file: Approval of ANDA 76\u2013187, Mylan Pharmaceuticals Inc, Levothyroxine Sodium Tablets. Available at: http:\/\/www.fda.gov\/cder\/foi\/anda\/2002\/076187_Bioequiv_Corresp.pdf. Accessed June 5, 2002."},{"key":"71054_CR35","unstructured":"Food and Drug Administration. Advisory Committe for Pharmaceutical Science. Record of Proceedings. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/transcripts\/3926T2.pdf. Accessed November 15, 2004."},{"key":"71054_CR36","unstructured":"Hubbard WK. Request that the Commissioner of Food and Drug take action described methodology for oral levothyroxine sodium drug products: Reply to Petitioners. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ dailys\/04\/June04\/062904\/03p-0387-pdn0001-vol5.pdf.Accessed June 23, 2004."},{"key":"71054_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1089\/1050725041517138","volume":"14","author":"American Thyroid Association, The Endocrine Society, American Association of Clinical Endocrinologists","year":"2004","unstructured":"American Thyroid Association, The Endocrine Society, American Association of Clinical Endocrinologists. Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium.Thyroid. 2004;14:486.","journal-title":"Thyroid."},{"key":"71054_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1210\/jc.75.2.344","volume":"75","author":"LA Burmeister","year":"1992","unstructured":"Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.J Clin Endocrinol Metab. 1992;75:344\u2013350.","journal-title":"J Clin Endocrinol Metab."},{"key":"71054_CR39","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1210\/jc.80.10.2873","volume":"80","author":"JH Oppenheimer","year":"1995","unstructured":"Oppenheimer JH, Braverman LE, Toft A, Jackson IM, Ladenson PW. A therapeutic controversy. Thyroid hormone treatment when and what?J Clin Endocrinol Metab. 1995;80:2873\u20132883.","journal-title":"J Clin Endocrinol Metab."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/aapsj070107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/aapsj070107\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/aapsj070107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/aapsj070107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T23:41:50Z","timestamp":1559605310000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/aapsj070107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["71054"],"URL":"https:\/\/doi.org\/10.1208\/aapsj070107","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}